Eidos Therapeutics, Inc.

Eidos Therapeutics, Inc. insiders are currently net buyers of EIDX stock, showing bullish sentiment over the past 90 days. Executives have purchased $439.7M while selling $27.2M, resulting in a positive net flow of $412.5M. This buying activity represents 94% of total transaction volume.

Eidos Therapeutics, Inc. has 12 active insiders who have filed SEC Form 4 transactions in the past 90 days. Ali J. Satvat (Executive) leads with 12 transactions totaling $119.8M. Neil Kumar (Executive) follows with 12 transactions worth $119.8M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Eidos Therapeutics, Inc.'s current score of 94/100 indicates bullish insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $439.7M in purchases versus $27.2M in sales.

The most recent insider transaction occurred on Jan 26, 2021, when Inc. Bridgebio Pharma, (Executive) acquired 14,428,836 shares at $0.00 per share for $0. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, EIDX insider trading sentiment is currently bullish with an Alignment Score of 94/100. The net insider flow of $412.5M reflects accumulation, with 94% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Eidos Therapeutics, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At EIDX, we track all Form 4 filings—currently showing 216 transactions from 12 insiders over 90 days.

A 10b5-1 plan allows Eidos Therapeutics, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At EIDX, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at EIDX appears discretionary, making insider signals more meaningful.

You can monitor Eidos Therapeutics, Inc. (EIDX) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 12 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Eidos Therapeutics, Inc.'s current score of 94/100 indicates strong bullish sentiment with executives accumulating shares. This is calculated from $439.7M in purchases versus $27.2M in sales over 90 days, resulting in a net flow of $412.5M.

SEC Form 4 filings are mandatory reports that Eidos Therapeutics, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At EIDX, the most common type is "S" with 34 occurrences. The most recent Form 4 was filed on Jan 26, 2021 by Inc. Bridgebio Pharma,.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Eidos Therapeutics, Inc., approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at EIDX represents discretionary decisions with more informational value.